{"content":"<li class=\"n-box-item date-title\" data-end=\"1506743999\" data-start=\"1506657600\" data-txt=\"Monday, December 23, 2019\">Friday, September 29, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3298552\" data-ts=\"1506724639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRN\" target=\"_blank\">TRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298552-trinity-industries-wins-reversal-of-663m-fraud-judgment-over-guardrails\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trinity Industries wins reversal of $663M fraud judgment over guardrails</a></h4><ul>     <li>Trinity Industries (NYSE:<a href='https://seekingalpha.com/symbol/TRN' title='Trinity Industries Inc.'>TRN</a>) <font color='green'>+9.7%</font> AH on news that the $663M guardrail fraud judgment against the company was <a href=\"http://www.reuters.com/article/us-trinity-ind-inc-judgment/trinity-wins-reversal-of-663-million-u-s-judgment-over-guardrails-idUSKCN1C4343\" target=\"_blank\">reversed</a> by a federal appeals court.</li>     <li>A whistleblower lawsuit had accused TRN of defrauding the U.S. government through the sale of defective guardrails, but the 5th U.S. Circuit Court of Appeals in New Orleans ruled that the finding of fraud under the federal False Claims Act underlying the judgement could not stand.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298552\" data-linked=\"Trinity Industries wins reversal of $663M fraud judgment over guardrails\" data-tweet=\"$TRN - Trinity Industries wins reversal of $663M fraud judgment over guardrails https://seekingalpha.com/news/3298552-trinity-industries-wins-reversal-of-663m-fraud-judgment-over-guardrails?source=tweet\" data-url=\"https://seekingalpha.com/news/3298552-trinity-industries-wins-reversal-of-663m-fraud-judgment-over-guardrails\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298551\" data-ts=\"1506723841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIG\" target=\"_blank\">AIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298551-u-s-ends-federal-oversight-of-aig\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. ends federal oversight of AIG</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/AIG' title='American International Group Inc'>AIG</a> <font color='green'>+1.5%</font> AH after U.S. officials <a href=\"https://www.wsj.com/articles/u-s-rescinds-federal-oversight-of-aig-1506722576\" target=\"_blank\">remove federal oversight</a> of the insurer, which now is roughly half its size at the time of the financial crisis, when it was on the verge of collapse.</li>     <li>The Financial Stability Oversight Council votes 6-3 \u200bto rescind AIG&rsquo;s designation as a &ldquo;systemically important financial institution.&rdquo;</li>     <li>The council applied the label to AIG in July 2013 and affirmed its findings every year thereafter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298551\" data-linked=\"U.S. ends federal oversight of AIG\" data-tweet=\"$AIG - U.S. ends federal oversight of AIG https://seekingalpha.com/news/3298551-u-s-ends-federal-oversight-of-aig?source=tweet\" data-url=\"https://seekingalpha.com/news/3298551-u-s-ends-federal-oversight-of-aig\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298542\" data-ts=\"1506720909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298542-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/TRN' title='Trinity Industries Inc.'>TRN</a> <font color='green'>+8.15%</font>. <a href='https://seekingalpha.com/symbol/QNST' title='QuinStreet, Inc.'>QNST</a> <font color='green'>+4.13%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+3.37%</font>. <a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+3.3%</font>. <a href='https://seekingalpha.com/symbol/AVXS' title='AveXis'>AVXS</a> <font color='green'>+2.85%</font>.</li>     <li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='red'>-3.28%</font>. <a href='https://seekingalpha.com/symbol/LKSD' title='LSC Communications, Inc.'>LKSD</a> <font color='red'>-2.96%</font>. <a href='https://seekingalpha.com/symbol/XENT' title='Intersect ENT'>XENT</a> <font color='red'>-2.72%</font>. <a href='https://seekingalpha.com/symbol/RYAAY' title='Ryanair Holdings PLC'>RYAAY</a> <font color='red'>-2.65%</font>. <a href='https://seekingalpha.com/symbol/TEAM' title='Atlassian'>TEAM</a> <font color='red'>-1.88%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298542\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$TRN $QNST $ACRX - After Hours Gainers / Losers https://seekingalpha.com/news/3298542-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3298542-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298540\" data-ts=\"1506719916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298540-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/IWC' title='iShares Micro-Cap ETF'>IWC</a> <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/XHB' title='SPDR Homebuilders ETF'>XHB</a> <font color='green'>+3.5%</font>. <a href='https://seekingalpha.com/symbol/IJS' title='iShares S&P Small-Cap 600 Value ETF'>IJS</a> <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/FCG' title='First Trust Natural Gas ETF'>FCG</a> <font color='green'>+2.9%</font>. <a href='https://seekingalpha.com/symbol/REMX' title='VanEck Vectors Rare Earth/Strategic Metals ETF'>REMX</a> <font color='green'>+2.9%</font>.</li>     <li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='red'>-5.0%</font>. <a href='https://seekingalpha.com/symbol/BRF' title='VanEck Vectors Brazil Small-Cap ETF'>BRF</a> <font color='red'>-3.2%</font>. <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a> <font color='red'>-3.1%</font>. <a href='https://seekingalpha.com/symbol/DEM' title='WisdomTree Emerging Markets High Dividend ETF'>DEM</a> <font color='red'>-2.6%</font>. <a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a> <font color='red'>-2.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298540\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$IWC $XHB $IJS - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3298540-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3298540-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298517\" data-ts=\"1506716610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDR\" target=\"_blank\">CDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298517-reuters-snow-park-builds-activist-stake-in-cedar-realty-trust\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Snow Park builds activist stake in Cedar Realty Trust</a></h4><ul>     <li>Cedar Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/CDR' title='Cedar Realty Trust, Inc.'>CDR</a>) popped 3.1% in late trading following a Reuters report that activist hedge fund Snow Park Capital has <a href=\"https://www.reuters.com/article/us-cedar-realty-activist-snow-park-capit/exclusive-activist-snow-park-builds-stake-in-cedar-realty-trust-sources-idUSKCN1C42UU\" target=\"_blank\">built a stake</a> in the REIT and is urging an exploration of strategic options including a possible sale.</li><li>The talks between CDR and Snow Park reportedly are at an  early stage, and it is not known if CDR will decide to conduct a  strategic review or consider a challenge to its board,</li></ul><div class=\"tiny-share-widget\" data-id=\"3298517\" data-linked=\"Reuters: Snow Park builds activist stake in Cedar Realty Trust\" data-tweet=\"$CDR - Reuters: Snow Park builds activist stake in Cedar Realty Trust https://seekingalpha.com/news/3298517-reuters-snow-park-builds-activist-stake-in-cedar-realty-trust?source=tweet\" data-url=\"https://seekingalpha.com/news/3298517-reuters-snow-park-builds-activist-stake-in-cedar-realty-trust\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298505\" data-ts=\"1506715187\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPX\" target=\"_blank\">LPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298505-louisiana-pacificminus-5-after-bmo-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Louisiana-Pacific -5% after BMO downgrade</a></h4><ul>     <li>Lousiana-Pacific (<a href='https://seekingalpha.com/symbol/LPX' title='Louisiana-Pacific Corporation'>LPX</a> <font color='red'>-5.2%</font>) tumbles more than 5% after BMO Capital <a href=\"http://thefly.com/thestreet/realmoney/index.php/LPXid2616231/LPX-LouisianaPacific-downgraded--at-BMO-Capital\" target=\"_blank\">downgrades</a> shares to Underperform fro Market Perform with a $24 price target, citing valuation and upcoming supply increases to oriented strand board.</li>     <li>BMO believes the supply increases set to occur over the next 6-9 months will pressure OSB prices.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298505\" data-linked=\"Louisiana-Pacific -5% after BMO downgrade\" data-tweet=\"$LPX - Louisiana-Pacific -5% after BMO downgrade https://seekingalpha.com/news/3298505-louisiana-pacificminus-5-after-bmo-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3298505-louisiana-pacificminus-5-after-bmo-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298504\" data-ts=\"1506714499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTN\" target=\"_blank\">RTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298504-raytheon-raised-to-buy-deutsche-bank-on-coming-missile-defense-spending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raytheon raised to Buy at Deutsche Bank on coming missile defense spending</a></h4><ul>     <li>Raytheon (<a href='https://seekingalpha.com/symbol/RTN' title='Raytheon Company'>RTN</a> <font color='green'>+1.3%</font>) rises to 52-week highs as Deutsche Bank <a href=\"https://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Upgrades+Raytheon+%28RTN%29+to+Buy%3B+U.S.+Missile+Purse+String+to+Open/13342610.html\" target=\"_blank\">upgrades shares to Buy</a> from Hold with a $210 price target, raised from $180, as the stock most exposed to missile defense trends.</li>     <li>U.S. spending on missile defense has dropped nearly 25% in real dollar terms over the past decade, but Deutsche Bank sees politics and growing missile threats to U.S. territory setting the table for another leg up in missile defense spending which could claw back all the previous declines in relatively short order.</li>     <li>The firm also raises its stock price targets on Northrop Grumman (<a href='https://seekingalpha.com/symbol/NOC' title='Northrop Grumman Corporation'>NOC</a> <font color='green'>+1%</font>) to $325 from $285 and on Lockheed Martin (<a href='https://seekingalpha.com/symbol/LMT' title='Lockheed Martin'>LMT</a> <font color='green'>+0.3%</font>) to $340 from $305.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298504\" data-linked=\"Raytheon raised to Buy at Deutsche Bank on coming missile defense spending\" data-tweet=\"$RTN $RTN $NOC - Raytheon raised to Buy at Deutsche Bank on coming missile defense spending https://seekingalpha.com/news/3298504-raytheon-raised-to-buy-deutsche-bank-on-coming-missile-defense-spending?source=tweet\" data-url=\"https://seekingalpha.com/news/3298504-raytheon-raised-to-buy-deutsche-bank-on-coming-missile-defense-spending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298502\" data-ts=\"1506713333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCG\" target=\"_blank\">SCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298502-scana-hits-52-week-low-williams-downgrades-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SCANA hits 52-week low as Williams downgrades to Sell</a></h4><ul>     <li>SCANA (<a href='https://seekingalpha.com/symbol/SCG' title='SCANA Corporation'>SCG</a> <font color='red'>-4.7%</font>)&nbsp;sinks to 52-week lows as Williams Capital <a href=\"http://thefly.com/thestreet/realmoney/index.php/SCGid2616302/SCG-Scana-downgraded-to-Sell-from-Hold-at-Williams-Capital\" target=\"_blank\">downgrades shares to Sell</a> from Hold and cuts its price target to $40 from $50, a day after lowering its price target from $70.</li>     <li>On Thursday, SCG reportedly was the target of a <a href=\"http://www.live5news.com/story/36480145/lawsuit-filed-against-scana-corporation\" target=\"_blank\">new shareholder lawsuit</a> accusing the company of manipulating the stock in lying about the development of the V.C. Summer nuclear project, and Williams dramatically reducing its 2018-19 earnings estimates to reflect the likelihood of a regulatory outcome.</li>     <li>Also yesterday, South Carolina's Public Service Commission <a href=\"https://www.bizjournals.com/charlotte/news/2017/09/28/scana-says-v-c-summer-rate-proposal-could-threaten.html\" target=\"_blank\">deferred action</a> on a petition by the state&rsquo;s customer advocate to suspend ~$37M per month in rates South Carolina Electric &amp; Gas charges customers for costs at the failed V.C. Summer plant and tasked a hearing officer to set up a schedule for considering the petition.</li>     <li>SCG praised the PSC&rsquo;s decision \"not to rush to judgment&rdquo; and prevent SCE&amp;G from collecting what amounts to $447M/year; Williams says it was somewhat encouraged by the tenor of the PSC's order to hold substantive hearings in the rate request.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298502\" data-linked=\"SCANA hits 52-week low as Williams downgrades to Sell\" data-tweet=\"$SCG - SCANA hits 52-week low as Williams downgrades to Sell https://seekingalpha.com/news/3298502-scana-hits-52-week-low-williams-downgrades-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3298502-scana-hits-52-week-low-williams-downgrades-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298500\" data-ts=\"1506711466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298500-deep-divisions-remain-freeport-indonesia-over-divestment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deep divisions remain between Freeport, Indonesia over divestment</a></h4><ul>     <li>Freeport McMoRan (<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='red'>-2.1%</font>) appears to <a href=\"http://www.reuters.com/article/us-freeport-mcmoran-indonesia/freeport-at-loggerheads-with-indonesia-over-divestment-letter-idUSKCN1C42HJ\" target=\"_blank\">remain at loggerheads</a> with Indonesia, as a company letter to the country's finance minister expresses strong disagreement with the government's proposed divestment plan, Reuters reports.</li>     <li>&ldquo;Freeport is prepared to discuss a path forward but cannot negotiate on the basis of the government&rsquo;s Sept. 28 proposal,&rdquo; CEO&nbsp;Richard Adkerson says in the letter, which indicates continued deep divisions over issues related to the valuation, timing and structure of the divestment.</li>     <li>Under Indonesia&rsquo;s proposal, the government said it has the financial capacity to take over the shares by Dec. 31, FCX says in the letter; FCX wants an initial divestment, as soon as possible, through an IPO, with full divestment done in stages over several years.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298500\" data-linked=\"Deep divisions remain between Freeport, Indonesia over divestment\" data-tweet=\"$FCX - Deep divisions remain between Freeport, Indonesia over divestment https://seekingalpha.com/news/3298500-deep-divisions-remain-freeport-indonesia-over-divestment?source=tweet\" data-url=\"https://seekingalpha.com/news/3298500-deep-divisions-remain-freeport-indonesia-over-divestment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298498\" data-ts=\"1506711325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298498-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> WPCS <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a> <font color='green'>+16%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TNTR-OLD' title='Tintri, Inc.'>TNTR-OLD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298498\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$DCAR $VERI $HMNY - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3298498-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298498-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298488\" data-ts=\"1506708253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIPT\" target=\"_blank\">AIPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298488-skyline-medical-nearing-completion-of-cytobioscience-merger-shares-ahead-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skyline Medical nearing completion of CytoBioscience merger; shares ahead 15%</a></h4><ul><li>Skyline Medical (SKLN <font color='green'>+15.5%</font>) <a href=\"https://seekingalpha.com/pr/16955413-skyline-medical-provides-update-pending-merger-cytobioscience\" target=\"_blank\">reports </a>that it has submitted all the relevant paperwork to Nasdaq related to its planned merger with CytoBioscience. Additional financial and due diligence documentation to be provided by third parties will be filed in the coming weeks. The company expects the deal to be completed by the end of October.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298488\" data-linked=\"Skyline Medical nearing completion of CytoBioscience merger; shares ahead 15%\" data-tweet=\"$AIPT $POAI - Skyline Medical nearing completion of CytoBioscience merger; shares ahead 15% https://seekingalpha.com/news/3298488-skyline-medical-nearing-completion-of-cytobioscience-merger-shares-ahead-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3298488-skyline-medical-nearing-completion-of-cytobioscience-merger-shares-ahead-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298486\" data-ts=\"1506708059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298486-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/KRA' title='Kraton Corporation'>KRA</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/OMN' title='OMNOVA Solutions Inc.'>OMN</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ACH' title='Aluminum Corporation of China Ltd'>ACH</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ROYT' title='Pacific Coast Oil Trust'>ROYT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ORIG' title='Ocean Rig UDW Inc.'>ORIG</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/REXX' title='Rex Energy Corporation'>REXX</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298486\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$ROSE $KRA $OMN - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3298486-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298486-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298483\" data-ts=\"1506707821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298483-jaguar-health-prices-stock-offering-0_20-shares-plummet-50\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jaguar Health prices stock offering at $0.20; shares plummet 50%</a></h4><ul><li>Nano cap Jaguar Health (<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Animal Health, Inc.'>JAGX</a> <font color='red'>-50.2%</font>) craters on a 16x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16955408-jaguar-health-prices-4_25-million-public-offering-common-stock\" target=\"_blank\">public offering</a> of 21.25M shares of common stock at $0.20 per share. Underwriters over-allotment is an additional 3,187,500 shares. Gross proceeds should be ~$4.25M. Closing date is October 3.</li><li>Net proceeds will fund the commercialization of Mytesi, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298483\" data-linked=\"Jaguar Health prices stock offering at $0.20; shares plummet 50%\" data-tweet=\"$JAGX - Jaguar Health prices stock offering at $0.20; shares plummet 50% https://seekingalpha.com/news/3298483-jaguar-health-prices-stock-offering-0_20-shares-plummet-50?source=tweet\" data-url=\"https://seekingalpha.com/news/3298483-jaguar-health-prices-stock-offering-0_20-shares-plummet-50\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298479\" data-ts=\"1506707015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298479-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='green'>+44%</font>. <a href='https://seekingalpha.com/symbol/FBSS' title='Fauquier Bankshares, Inc.'>FBSS</a> <font color='green'>+9%</font>.<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings'>YIN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a> <font color='red'>-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298479\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$RTNB $FBSS $YIN - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3298479-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298479-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298467\" data-ts=\"1506703329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298467-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a> <font color='green'>+147%</font>. <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='green'>+44%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+28%</font>. WPCS <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ATEN' title='A10 Networks, Inc.'>ATEN</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/LKSD' title='LSC Communications, Inc.'>LKSD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/REXX' title='Rex Energy Corporation'>REXX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/EVI' title='EnviroStar, Inc.'>EVI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298467\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ZGNX $RTNB $VERI - Midday Gainers / Losers https://seekingalpha.com/news/3298467-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3298467-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298464\" data-ts=\"1506701980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEGI\" target=\"_blank\">PEGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298464-pattern-energyminus-3-on-effects-from-texas-puerto-rico-weather\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pattern Energy -3% on effects from Texas, Puerto Rico weather</a></h4><ul>     <li>Pattern Energy (<a href='https://seekingalpha.com/symbol/PEGI' title='Pattern Energy Group Inc.'>PEGI</a> <font color='red'>-2.9%</font>) <a href=\"https://seekingalpha.com/pr/16955167-pattern-energy-provides-operations-financial-guidance-update-light-recent-weather-events\" target=\"_blank\">reaffirms</a> its target for 2017 cash available for distribution of $140M-$165M but expects Q3 production to come in below its long-term average in light of weather events in Texas and Puerto Rico.</li>     <li>PEGI also lowers its Q3 CAFD guidance to $5M-$11M from $12M-$14M based primarily on wind conditions that were below the long-term average.</li>     <li>PEGI says its operations team has been able to respond effectively to events and are working with the Puerto Rico authorities to support efforts to restore power.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298464\" data-linked=\"Pattern Energy -3% on effects from Texas, Puerto Rico weather\" data-tweet=\"$PEGI - Pattern Energy -3% on effects from Texas, Puerto Rico weather https://seekingalpha.com/news/3298464-pattern-energyminus-3-on-effects-from-texas-puerto-rico-weather?source=tweet\" data-url=\"https://seekingalpha.com/news/3298464-pattern-energyminus-3-on-effects-from-texas-puerto-rico-weather\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298461\" data-ts=\"1506700970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298461-analysts-weight-in-on-blackberry-q2-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts weight in on BlackBerry Q2 beat</a></h4><ul><li>        Analysts weight in after BlackBerry&rsquo;s (BBRY) Q2 beats yesterday.</li><li>               Canaccord Genuity has BlackBerry at a Hold with $10 price target.&nbsp;</li><li>               Analyst Michael Walkley says the company&rsquo;s $1.9B in net cash can provide growth capital through hiring and acquisitions. He expects steady growth in all units but potential acquisitions are the most likely path to the material upside.&nbsp;</li><li>               Raymond James puts BlackBerry at Market Perform and a $11 price target awaiting a more balanced risk-reward profile.&nbsp;</li><li>               Analyst Steven Li notes that enterprise and QNX auto software have growth potential but both were flat on the year this quarter.&nbsp;</li><li>               MKM Partners&rsquo; Michael Genovese calls the stock expensive based on the company&rsquo;s FY18 guidance and the analyst&rsquo;s FY19 outlook.&nbsp;</li><li>               Sees tailwinds in connected cars, IoT, and cyber security but revenue ramp could take at least two years.&nbsp;</li><li>                  Genovese rates the company Neutral with a $10 price target.    </li><li>               Source: Bloomberg First Word&nbsp;</li><li>               BlackBerry shares are&nbsp;<font color='green'>up 5.73%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298119-blackberry-8-percent-q2-beats-positive-guidance\" target=\"_blank\">BlackBerry up 8% after Q2 beats and positive guidance</a> (Sept. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298360-blackberry-tokyo-electron-device-sign-software-agreement\" target=\"_blank\">BlackBerry and Tokyo Electron Device sign software agreement</a> (Sept. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298461\" data-linked=\"Analysts weight in on BlackBerry Q2 beat\" data-tweet=\"$BB - Analysts weight in on BlackBerry Q2 beat https://seekingalpha.com/news/3298461-analysts-weight-in-on-blackberry-q2-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3298461-analysts-weight-in-on-blackberry-q2-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298460\" data-ts=\"1506700891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298460-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FARM' title='Farmer Brothers Company'>FARM</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/TSN' title='Tyson Foods Inc.'>TSN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/JOUT' title='Johnson Outdoors Inc.'>JOUT</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='red'>-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298460\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$FARM $TSN $JOUT - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3298460-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298460-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298458\" data-ts=\"1506700612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298458-selling-in-ionis-and-biogen-overdone-mizuho\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Selling in Ionis and Biogen overdone - Mizuho</a></h4><ul><li>Mizuho Securities calls the selling in Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='red'>-3.4%</font>) and nusinersen licensee Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='red'>-0.8%</font>) overdone citing the lack of confirmation of any treatment-related deaths and FAERS'&nbsp; lack of distinction between the causes of adverse events.</li><li>It says Biogen is preparing a statement to address the situation.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3298458\" data-linked=\"Selling in Ionis and Biogen overdone - Mizuho\" data-tweet=\"$IONS $IONS $BIIB - Selling in Ionis and Biogen overdone - Mizuho https://seekingalpha.com/news/3298458-selling-in-ionis-and-biogen-overdone-mizuho?source=tweet\" data-url=\"https://seekingalpha.com/news/3298458-selling-in-ionis-and-biogen-overdone-mizuho\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298456\" data-ts=\"1506699972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTCT\" target=\"_blank\">PTCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298456-barclays-sees-24-downside-risk-on-ptc-therapeutics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays sees 24% downside risk on PTC Therapeutics</a></h4><ul><li>Citing its lack of confidence in the effectiveness of Translarna (ataluren) in DMD and the FDA's request for more data to prove it works, Barclays lowers its price target for PTC Therapeutics (<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='green'>+12.4%</font>) to $15 (24% downside risk) from $22.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298268-fda-ad-com-says-data-ptcs-translarna-inclusive-needed-prove-efficacy\" target=\"_blank\">FDA Ad Com says data on PTC's Translarna inclusive, more needed to prove efficacy</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298456\" data-linked=\"Barclays sees 24% downside risk on PTC Therapeutics\" data-tweet=\"$PTCT - Barclays sees 24% downside risk on PTC Therapeutics https://seekingalpha.com/news/3298456-barclays-sees-24-downside-risk-on-ptc-therapeutics?source=tweet\" data-url=\"https://seekingalpha.com/news/3298456-barclays-sees-24-downside-risk-on-ptc-therapeutics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298450\" data-ts=\"1506698305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTCT\" target=\"_blank\">PTCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298450-ptc-rollercoaster-shares-up-almost-40-from-tuesday-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PTC rollercoaster, shares up almost 40% from Tuesday low</a></h4><ul><li>PTC Therapeutics (<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='green'>+11.2%</font>) is the latest example of why biotech investing is such a thrill ride. Shares are up over 37% from Tuesday's low of $14.56. They lost over 30% of their value leading up to yesterday's FDA Ad Com meeting on Translarna.</li><li>Today's action appears to be related to the selling in Sarepta Therapeutics (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='red'>-3.6%</font>) stoked by a <a href=\"https://postimg.org/image/ysznbtug5/\" target=\"_blank\">screen shot</a> circulating on line that shows 11 adverse events, including three deaths, in patients treated with EXONDYS 51 (eteplirsen).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298442-ionis-sarepta-pressure-end-quarter-stock-play-rumors\" target=\"_blank\">Ionis and Sarepta under pressure on end-of-quarter stock play rumors</a> (Sept. 29)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298268-fda-ad-com-says-data-ptcs-translarna-inclusive-needed-prove-efficacy\" target=\"_blank\">FDA Ad Com says data on PTC's Translarna inclusive, more needed to prove efficacy</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298450\" data-linked=\"PTC rollercoaster, shares up almost 40% from Tuesday low\" data-tweet=\"$PTCT $PTCT $SRPT - PTC rollercoaster, shares up almost 40% from Tuesday low https://seekingalpha.com/news/3298450-ptc-rollercoaster-shares-up-almost-40-from-tuesday-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3298450-ptc-rollercoaster-shares-up-almost-40-from-tuesday-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298447\" data-ts=\"1506697646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APH\" target=\"_blank\">APH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298447-bofaml-upgrades-amphenol-raises-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML upgrades Amphenol, raises price target</a></h4><ul><li>        Bank of America Merrill Lynch <a href=\"https://www.streetinsider.com/Analyst+Comments/BofAMerrill+Lynch+Upgrades+Amphenol+%28APH%29+to+Buy/13342074.html\" target=\"_blank\">upgrades</a> Amphenol (NYSE:<a href='https://seekingalpha.com/symbol/APH' title='Amphenol Corporation'>APH</a>) from Neutral to Buy and ups the price target from $79 to $100.</li><li>               Analyst Wamsi Mohan is encouraged by growth expansion and organic recovery trends that should continue beyond the end of this year. Mohan sees tailwinds in the automotive, industrial, and military sectors.&nbsp;</li><li>               Amphenol shares are&nbsp;<font color='green'>up 2.55%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298447\" data-linked=\"BofAML upgrades Amphenol, raises price target\" data-tweet=\"$APH - BofAML upgrades Amphenol, raises price target https://seekingalpha.com/news/3298447-bofaml-upgrades-amphenol-raises-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3298447-bofaml-upgrades-amphenol-raises-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298424\" data-ts=\"1506697248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298424-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a> <font color='green'>+116%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NNVC' title='NanoViricides, Inc.'>NNVC</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/AHPI' title='Allied Healthcare Products, Inc.'>AHPI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298424\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$ZGNX $CAPR $PTCT - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3298424-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3298424-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298442\" data-ts=\"1506697031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298442-ionis-and-sarepta-under-pressure-on-end-of-quarter-stock-play-rumors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ionis and Sarepta under pressure on end-of-quarter stock play rumors</a></h4><ul><li>Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='red'>-5.6%</font>) and Sarepta Therapeutics (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='red'>-7.5%</font>) are both selling off on increased volume in apparent reaction to rumors of deaths related to <a href=\"https://twitter.com/BursatilBiotech/status/913776819886858240/photo/1\" target=\"_blank\">Spinraza </a>(nusinersen) and<a href=\"https://postimg.org/image/ysznbtug5/\" target=\"_blank\"> EXONDYS 51</a> (eteplirsen), respectively. The action reeks of end-of-quarter efforts to depress prices, especially related to Spinraza since the prognosis is poor for SMA babies.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3298442\" data-linked=\"Ionis and Sarepta under pressure on end-of-quarter stock play rumors\" data-tweet=\"$IONS $IONS $SRPT - Ionis and Sarepta under pressure on end-of-quarter stock play rumors https://seekingalpha.com/news/3298442-ionis-and-sarepta-under-pressure-on-end-of-quarter-stock-play-rumors?source=tweet\" data-url=\"https://seekingalpha.com/news/3298442-ionis-and-sarepta-under-pressure-on-end-of-quarter-stock-play-rumors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298445\" data-ts=\"1506696974\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABA\" target=\"_blank\">BABA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298445-alibaba-leads-investment-round-in-cloud-database-server-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alibaba leads investment round in cloud database server company</a></h4><ul><li>        Alibaba (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>) leads a $27M investment round in open source database server company MariaDB.</li><li>               <a href=\"https://techcrunch.com/2017/09/29/alibaba-mariadb/?ncid=rss&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\">TechCrunch</a> sources say Alibaba will contribute $23.6M of the round, which will push MariaDB&rsquo;s value to about $354M.&nbsp;</li><li>               Alibaba engineer Feng Yu will join the board of MariaDB as part of the investment.&nbsp;</li><li>               The investment could benefit Alibaba&rsquo;s growing cloud business as the company searches for a second European data center location and tries to take on market titan Amazon Web Services.&nbsp;</li><li>               Alibaba held 2.6% of the cloud infrastructure services market in Q2, according to <a href=\"https://www.cnbc.com/2017/09/07/adobe-chooses-azure-as-its-preferred-cloud-for-sign.html\" target=\"_blank\">Canalys</a>, which comes in far behind AWS&rsquo; 30.3% but is catching ground on Google&rsquo;s 5.9% share. &nbsp;&nbsp;</li><li>Alibaba shares are&nbsp;<font color='green'>up 1.3%</font>.&nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298253-alibaba-searches-new-european-data-center-location\" target=\"_blank\">Alibaba searches for new European data center location</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298445\" data-linked=\"Alibaba leads investment round in cloud database server company\" data-tweet=\"$BABA - Alibaba leads investment round in cloud database server company https://seekingalpha.com/news/3298445-alibaba-leads-investment-round-in-cloud-database-server-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3298445-alibaba-leads-investment-round-in-cloud-database-server-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298443\" data-ts=\"1506696591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBHT\" target=\"_blank\">JBHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298443-trucking-stocks-rev-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trucking stocks rev higher</a></h4><ul> <li>There are strong gains in the trucking sector after Stifel Nicolaus forecasts growth to pick up with the \"mother of call capacity shortages\" around the corner as hurricane-related rebuilding accelerates.</li> <li>Stifel lifts J.B. Hunt (<a href='https://seekingalpha.com/symbol/JBHT' title='J.B. Hunt Transport Services, Inc.'>JBHT</a> <font color='green'>+1.7%</font>), Heartland Express (<a href='https://seekingalpha.com/symbol/HTLD' title='Heartland Express, Inc.'>HTLD</a> <font color='green'>+5.8%</font>) and USA Truck (<a href='https://seekingalpha.com/symbol/USAK' title='USA Truck, Inc.'>USAK</a> <font color='green'>+9.5%</font>) to Buy ratings off the expectation for a pricing surge.</li> <li>The positive spin from Stifel appears to be aiding sentiment on Patriot Transportation (<a href='https://seekingalpha.com/symbol/PATI' title='Patriot Transportation Holding, Inc.'>PATI</a> <font color='green'>+3.3%</font>), Knight-Swift (<a href='https://seekingalpha.com/symbol/KNX' title='Knight-Swift Transportation Holdings Inc.'>KNX</a> <font color='green'>+1.8%</font>), Schneider National (<a href='https://seekingalpha.com/symbol/SNDR' title='Schneider National'>SNDR</a> <font color='green'>+3.5%</font>), Marten Transport (<a href='https://seekingalpha.com/symbol/MRTN' title='Marten Transport, Ltd.'>MRTN</a> <font color='green'>+0.5%</font>) and ArcBest (<a href='https://seekingalpha.com/symbol/ARCB' title='ArcBest Corporation'>ARCB</a> <font color='green'>+1.4%</font>) as well.</li> <li>Sources: CNBC and Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3298443\" data-linked=\"Trucking stocks rev higher\" data-tweet=\"$JBHT $JBHT $HTLD - Trucking stocks rev higher https://seekingalpha.com/news/3298443-trucking-stocks-rev-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3298443-trucking-stocks-rev-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298440\" data-ts=\"1506695940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USB\" target=\"_blank\">USB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298440-regional-banks-welcome-talk-of-warsh-next-fed-chair\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regional banks welcome talk of Warsh as next Fed chair</a></h4><ul><li><a href=\"https://seekingalpha.com/news/3298433-kevin-warsh-interviewed-trump-mnuchin-fed-chairman\" target=\"_blank\">The <em>WSJ</em> earlier reported</a> the former Fed governor as meeting yesterday with the president and the Treasury secretary to discuss the job, and prediction markets are painting Warsh as the clear favorite.</li><li>That's seen as good for banks, particularly the regional players, as Warsh is thought to be in favor of regulatory rollback.</li><li>The <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> is&nbsp;<font color='green'>up 1%</font>, and <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a>&nbsp;<font color='green'>0.9%</font>.</li><li>U.S. Bancorp (<a href='https://seekingalpha.com/symbol/USB' title='U.S. Bancorp'>USB</a> <font color='green'>+0.6%</font>), Regions Financial (<a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a> <font color='green'>+1.3%</font>), New York Community (<a href='https://seekingalpha.com/symbol/NYCB' title='New York Community Bancorp Inc.'>NYCB</a> <font color='green'>+0.9%</font>), KeyCorp (<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a> <font color='green'>+1%</font>), BB&amp;T (<a href='https://seekingalpha.com/symbol/BBT' title='BB&T Corporation'>BBT</a> <font color='green'>+1.1%</font>), Fifth Third (<a href='https://seekingalpha.com/symbol/FITB' title='Fifth Third Bancorp'>FITB</a> <font color='green'>+1.4%</font>), M&amp;T (<a href='https://seekingalpha.com/symbol/MTB' title='M&T Bank Corporation'>MTB</a> <font color='green'>+1.4%</font>), Zions (<a href='https://seekingalpha.com/symbol/ZION' title='Zions Bancorporation'>ZION</a> <font color='green'>+1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298440\" data-linked=\"Regional banks welcome talk of Warsh as next Fed chair\" data-tweet=\"$USB $KRE $KBE - Regional banks welcome talk of Warsh as next Fed chair https://seekingalpha.com/news/3298440-regional-banks-welcome-talk-of-warsh-next-fed-chair?source=tweet\" data-url=\"https://seekingalpha.com/news/3298440-regional-banks-welcome-talk-of-warsh-next-fed-chair\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298438\" data-ts=\"1506695200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEHR\" target=\"_blank\">AEHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298438-aehr-test-systems-up-after-q1-beats-follow-on-orders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aehr Test Systems up after Q1 beats, follow-on orders</a></h4><ul><li>           Aehr Test Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/AEHR' title='Aehr Test Systems'>AEHR</a>) shares are&nbsp;<font color='green'>up 6.53%&nbsp;</font>after yesterday&rsquo;s Q1 revenue and EPS beats with a reaffirmed guidance. </li><li> The company also <a href=\"https://seekingalpha.com/pr/16954658-aehr-test-systems-receives-follow-orders-fox-xp-test-burn-solution\" target=\"_blank\">announces</a> receiving $2.7M in follow-on orders from a subcontractor for the FOX-XP Test and Burn-in System customer. &nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3298277-aehr-test-systems-beats-0_02-beats-revenue\" target=\"_blank\">Aehr Test Systems beats by $0.02, beats on revenue</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298438\" data-linked=\"Aehr Test Systems up after Q1 beats, follow-on orders\" data-tweet=\"$AEHR - Aehr Test Systems up after Q1 beats, follow-on orders https://seekingalpha.com/news/3298438-aehr-test-systems-up-after-q1-beats-follow-on-orders?source=tweet\" data-url=\"https://seekingalpha.com/news/3298438-aehr-test-systems-up-after-q1-beats-follow-on-orders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298432\" data-ts=\"1506694129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAIN\" target=\"_blank\">HAIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298432-hain-celestial-higher-after-speculation-over-conagra-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hain Celestial higher after speculation over ConAgra interest</a></h4><ul> <li>Hain Celestial (NASDAQ:<a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a>) is <font color='green'>up 3.05%</font> after Dealreporter speculates on a potential bid from ConAgra Brands (<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a> <font color='green'>+0.7%</font>).</li> <li>Dealreports points to the tone from ConAgra management during yesterday's earnings call.</li> <li><a href=\"https://seekingalpha.com/article/4110355-conagra-foods-cag-ceo-sean-connolly-q1-2018-results-earnings-call-transcript?part=single\" target=\"_blank\">ConAgra earnings call transcript</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3298432\" data-linked=\"Hain Celestial higher after speculation over ConAgra interest\" data-tweet=\"$HAIN $HAIN $CAG - Hain Celestial higher after speculation over ConAgra interest https://seekingalpha.com/news/3298432-hain-celestial-higher-after-speculation-over-conagra-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3298432-hain-celestial-higher-after-speculation-over-conagra-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298427\" data-ts=\"1506693673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298427-merck-bails-on-future-hcv-drugs-shares-down-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merck bails on future HCV drugs; shares down 1%</a></h4><ul><li>Citing a crowded market, Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='red'>-0.6%</font>) has <a href=\"https://www.wsj.com/articles/merck-abandons-new-hepatitis-c-drugs-amid-crowded-market-1506690197\" target=\"_blank\">decided to stop</a> development on new treatments for hepatitis C virus &#40;HCV&#41; infection. It will continue to support Zepatier (elbasvir and grazoprevir) however.</li><li>It recently recorded a $2.9B impairment charge related to R&amp;D for antiviral uprifosbuvir, acquired via its takeout of Idenix Pharmaceuticals in 2014.</li><li>Johnson &amp; Johnson (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) also terminated development of its HCV med, refocusing its efforts on hepatitis B where there is less competition.</li><li>Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='red'>-1.8%</font>)&nbsp;remains the top player in HCV, although sales have been declining since 2015.</li><li>Related ticker: (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='red'>-0.3%</font>)</li><li>Source: WSJ</li></ul><div class=\"tiny-share-widget\" data-id=\"3298427\" data-linked=\"Merck bails on future HCV drugs; shares down 1%\" data-tweet=\"$MRK $MRK $JNJ - Merck bails on future HCV drugs; shares down 1% https://seekingalpha.com/news/3298427-merck-bails-on-future-hcv-drugs-shares-down-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3298427-merck-bails-on-future-hcv-drugs-shares-down-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298426\" data-ts=\"1506693502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBH\" target=\"_blank\">KBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298426-kb-homes-8-surge-leads-homebuilders-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KB Home&#39;s 8% surge leads homebuilders higher</a></h4><ul><li>Following KB Home's (<a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a> <font color='green'>+7.8%</font>) earnings <a href=\"https://seekingalpha.com/news/3298283-kb-home-drifts-higher-earnings-beat\" target=\"_blank\">beat last night</a>, Mizuho's&nbsp;Haendel St. Juste throws in the towel on his Underperform rating, upgrading to Neutral. Acknowledging boosted margins thanks to the mix shift to California, St. Juste takes note of higher-than-anticipated labor and materials costs.</li><li>The homebuilder ETFs (<a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>, <a href='https://seekingalpha.com/symbol/XHB' title='SPDR Homebuilders ETF'>XHB</a>) are each&nbsp;<font color='green'>ahead about 0.5%</font>.</li><li>Hovnanian (<a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a> <font color='green'>+2.1%</font>), Toll Brothers (<a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers Inc.'>TOL</a> <font color='green'>+0.2%</font>), Lennar (<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a> <font color='green'>+1%</font>), Pulte (<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a> <font color='green'>+1.1%</font>), D.R. Horton (<a href='https://seekingalpha.com/symbol/DHI' title='D. R. Horton Inc.'>DHI</a> <font color='green'>+0.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298426\" data-linked=\"KB Home&#39;s 8% surge leads homebuilders higher\" data-tweet=\"$KBH $KBH $ITB - KB Home&#39;s 8% surge leads homebuilders higher https://seekingalpha.com/news/3298426-kb-homes-8-surge-leads-homebuilders-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3298426-kb-homes-8-surge-leads-homebuilders-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298411\" data-ts=\"1506691130\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298411-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a> <font color='green'>+149%</font>&nbsp;on the <a href=\"https://seekingalpha.com/news/3298357-zogenixs-lead-candidate-zx008-successful-late-stage-dravet-study-shares-212-percent-premarket\" target=\"_blank\">announcement</a> of its lead candidate ZX008 successful in late-stage Dravet study.</li>     <li><a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='green'>+30%.</font></li>     <li><a href='https://seekingalpha.com/symbol/SUNW' title='Sunworks, Inc.'>SUNW</a> <font color='green'>+26%</font>&nbsp;on largest&nbsp;<a href=\"https://seekingalpha.com/pr/16955005-sunworks-announces-largest-contract-award-date\" target=\"_blank\">contract award</a>&nbsp;to date.</li>     <li><a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='green'>+12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298307-aptevo-completes-sale-three-products-saol-therapeutics-74_5m\" target=\"_blank\">completion</a> of sale of three products to Saol.</li>     <li><a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+12%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+9%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298380-oppenheimer-sees-massive-upside-conns\" target=\"_blank\">positive</a> rating by&nbsp;Oppenheimer.</li>     <li><a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298401-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics'>VKTX</a> <font color='green'>+5%</font>&nbsp;on common stock purchase <a href=\"https://seekingalpha.com/news/3298382-viking-therapeutics-announces-purchase-agreements-16_25m-lincoln-park-capital\" target=\"_blank\">agreements</a> for up to $16.25M with Lincoln Park Capital.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298411\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$ZGNX $RTNB $SUNW - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3298411-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3298411-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298406\" data-ts=\"1506690612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298406-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a>&nbsp;<font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298396-yuma-energy-upsizes-stock-offering-prices-1-share\" target=\"_blank\">upsizing</a> and pricing of public offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298365-gw-pharma-slips-15-percent-premarket-zogenixs-successful-late-stage-study-zx008-dravet\" target=\"_blank\">Zogenix's</a> successful late-stage study of ZX008 in Dravet.</li><li><a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-9%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3298406\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$YUMA $GWPH $AEMD - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3298406-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3298406-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298401\" data-ts=\"1506689632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABMD\" target=\"_blank\">ABMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298401-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Abiomed (NASDAQ:<a href='https://seekingalpha.com/symbol/ABMD' title='ABIOMED, Inc.'>ABMD</a>) initiated with Buy rating and $195 (20% upside) price target by SunTrust.</li><li>Blueprint Medicines (NASDAQ:<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a>) initiated with Buy rating and $90 (31% upside)&nbsp;price target by BTIG Research.</li><li>Medpace Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MEDP' title='Medpace Holdings'>MEDP</a>) initiated with Market Perform rating by Raymond James.</li><li>Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) initiated with Buy rating and $200 (34% upside) price target by BTIG Research. Shares up&nbsp;<font color='green'>2%</font>&nbsp;premarket.</li><li>Regeneron Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) resumed with Overweight rating and $540 (24% upside) price target by Piper Jaffray.</li><li>Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a>) upgraded to Overweight with a $16 (69% upside) by Piper Jaffray. Shares up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li><li>Prothena (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTA' title='Prothena Corp plc'>PRTA</a>) price target lowered to $77 (14% upside) from $80 by BTIG Research on decision to stop development of PRX003. Shares down&nbsp;<font color='red'>7%&nbsp;</font>premarket.</li><li>Alcobra (ADHD) downgraded to Neutral by Roth Capital. Shares up&nbsp;<font color='green'>4%&nbsp;</font>premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298401\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$ABMD $ABMD $BPMC - Premarket analyst action - healthcare https://seekingalpha.com/news/3298401-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3298401-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298396\" data-ts=\"1506689345\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YUMA\" target=\"_blank\">YUMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298396-yuma-energy-upsizes-stock-offering-prices-1-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yuma Energy upsizes stock offering, prices at $1/share</a></h4><ul>     <li>Yuma Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a>) <font color='red'>-10.5%</font> premarket after <a href=\"https://seekingalpha.com/pr/16954965-yuma-energy-inc-announces-upsizing-pricing-public-offering-common-stock\" target=\"_blank\">upsizing its common stock offering</a> to 9.6M shares and pricing the offering at $1/share, with an over-allotment option to purchase up to an additional 1.44M shares.</li>     <li>Yuma plans to use the proceeds to provide for additional leasehold acquisitions in the Permian Basin, the drilling of a San Andres horizontal oil well along with a Devonian salt water disposal well and other field infrastructure, and for general working capital purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298396\" data-linked=\"Yuma Energy upsizes stock offering, prices at $1/share\" data-tweet=\"$YUMA - Yuma Energy upsizes stock offering, prices at $1/share https://seekingalpha.com/news/3298396-yuma-energy-upsizes-stock-offering-prices-1-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3298396-yuma-energy-upsizes-stock-offering-prices-1-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298392\" data-ts=\"1506688721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLYC\" target=\"_blank\">GLYC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298392-glycomimetics-registers-250m-mixed-shelf-offering-shares-down-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GlycoMimetics registers $250M mixed shelf offering; shares down 5% premarket</a></h4><ul><li>GlycoMimetics (NASDAQ:<a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a>) slips&nbsp;<font color='red'>5%</font>&nbsp;premarket on light volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1253689/000104746917006107/a2233418zs-3.htm\" target=\"_blank\">filing </a>of an S-3 for a $250M mixed shelf offering. Net proceeds will fund the manufacturing of GMI-1271, clinical trials, R&amp;D, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298392\" data-linked=\"GlycoMimetics registers $250M mixed shelf offering; shares down 5% premarket\" data-tweet=\"$GLYC - GlycoMimetics registers $250M mixed shelf offering; shares down 5% premarket https://seekingalpha.com/news/3298392-glycomimetics-registers-250m-mixed-shelf-offering-shares-down-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298392-glycomimetics-registers-250m-mixed-shelf-offering-shares-down-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298391\" data-ts=\"1506688535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRN\" target=\"_blank\">TRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298391-citi-sees-breakout-for-trinity-industries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi sees breakout for Trinity Industries</a></h4><ul> <li>Trinity Industries (NYSE:<a href='https://seekingalpha.com/symbol/TRN' title='Trinity Industries Inc.'>TRN</a>) breaks higher in early trading after Citi <a href=\"https://twitter.com/RatingsNetwork/status/913726483851509760\" target=\"_blank\">upgrades</a> the transportation stock to a Buy rating from Neutral.</li> <li>Analyst Prashant Rao points to the improving fundamentals at Trinity and sees some potential for activist investors to create a stir. Rao and team set a price target of $36 on Trinity.</li> <li>TRN <font color='green'>+1.44%</font> premarket to $31.63 vs. a 52-week trading range of $20.80 to $31.32.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298391\" data-linked=\"Citi sees breakout for Trinity Industries\" data-tweet=\"$TRN - Citi sees breakout for Trinity Industries https://seekingalpha.com/news/3298391-citi-sees-breakout-for-trinity-industries?source=tweet\" data-url=\"https://seekingalpha.com/news/3298391-citi-sees-breakout-for-trinity-industries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298387\" data-ts=\"1506688456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTA\" target=\"_blank\">PRTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298387-prothena-bails-on-psoriasis-candidate-prx003-after-early-stage-data-failed-to-show-sufficient\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prothena bails on psoriasis candidate PRX003 after early-stage data failed to show sufficient clinical benefit; shares down 6% premarket</a></h4><ul><li>Thinly traded Prothena (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTA' title='Prothena Corp plc'>PRTA</a>) is down&nbsp;<font color='red'>6%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16954649-prothena-reports-results-phase-1b-multiple-ascending-dose-study-prx003-patients-psoriasis\" target=\"_blank\">announcement </a>that it will not advance pipeline candidate PRX003 into mid-stage psoriasis studies. It decided to nix development after a Phase 1b clinical trial failed to show a clear enough relationship between biological activity and meaningful clinical benefit as measured by PASI 75 (75% improvement in symptoms).</li><li>PRX003 is a monoclonal antibody that binds to CD146, also known as melanoma cell adhesion molecule.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298387\" data-linked=\"Prothena bails on psoriasis candidate PRX003 after early-stage data failed to show sufficient clinical benefit; shares down 6% premarket\" data-tweet=\"$PRTA - Prothena bails on psoriasis candidate PRX003 after early-stage data failed to show sufficient clinical benefit; shares down 6% premarket https://seekingalpha.com/news/3298387-prothena-bails-on-psoriasis-candidate-prx003-after-early-stage-data-failed-to-show-sufficient?source=tweet\" data-url=\"https://seekingalpha.com/news/3298387-prothena-bails-on-psoriasis-candidate-prx003-after-early-stage-data-failed-to-show-sufficient\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298379\" data-ts=\"1506687674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTTR\" target=\"_blank\">RTTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298379-ritter-pharma-prices-equity-offering-shares-off-27-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ritter Pharma prices equity offering; shares off 27% premarket</a></h4><ul><li>Thinly traded nano cap Ritter Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a>) is down&nbsp;<font color='red'>27%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16955004-ritter-pharmaceuticals-inc-prices-23000-000-public-offering\" target=\"_blank\">announced </a>public equity offering expected to raise ~$23M.</li><li>The offering consists of Class A and Class B Units. Each Class A Unit represents 34.55M shares of common stock and five-year warrants to purchase 34.55M shares of common at $0.44 per share. Each Class B Unit consists of 9,180 shares of Series A Convertible Preferred Stock at $1,000 per share, convertible into 22.95M common shares.</li><li>Closing date is October 3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298379\" data-linked=\"Ritter Pharma prices equity offering; shares off 27% premarket\" data-tweet=\"$RTTR - Ritter Pharma prices equity offering; shares off 27% premarket https://seekingalpha.com/news/3298379-ritter-pharma-prices-equity-offering-shares-off-27-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298379-ritter-pharma-prices-equity-offering-shares-off-27-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298380\" data-ts=\"1506687153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CONN\" target=\"_blank\">CONN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298380-oppenheimer-sees-massive-upside-for-conns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer sees massive upside for Conn&#39;s</a></h4><ul> <li>Conn's (NASDAQ:<a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a>) is on the move after catching an upgrade from Oppenheimer to Outperform from Market Perform.</li> <li>The firm's high-flying price target of $40 reps 56% upside potential for shares.</li> <li>CONN <font color='green'>+6.43%</font> premarket to $27.30 (52-week high).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298380\" data-linked=\"Oppenheimer sees massive upside for Conn&#39;s\" data-tweet=\"$CONN - Oppenheimer sees massive upside for Conn&#39;s https://seekingalpha.com/news/3298380-oppenheimer-sees-massive-upside-for-conns?source=tweet\" data-url=\"https://seekingalpha.com/news/3298380-oppenheimer-sees-massive-upside-for-conns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298374\" data-ts=\"1506686709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298374-citi-raises-nvidia-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi raises Nvidia price target</a></h4><ul><li>        Citi <a href=\"https://www.streetinsider.com/Analyst+Comments/NVIDIA+%28NVDA%29+PT+Raised+to+%24210+at+Citi/13341813.html\" target=\"_blank\">raises</a> its Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) price target from $185 to $210 and maintains a Buy rating.</li><li>               Analyst Atif Malik cites AI market potential and says Nvidia is &ldquo;widely perceived as an underdog in inferencing given architecture optionality around the use of CPU, FPGA, and TPU.&rdquo;&nbsp;</li><li>               Nvidia shares are&nbsp;<font color='green'>up 1.71%&nbsp;</font>premarket to $178.68.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298161-google-assistant-comes-nvidia-shield-tv-today\" target=\"_blank\">Google Assistant comes to Nvidia Shield TV today</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298374\" data-linked=\"Citi raises Nvidia price target\" data-tweet=\"$NVDA - Citi raises Nvidia price target https://seekingalpha.com/news/3298374-citi-raises-nvidia-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3298374-citi-raises-nvidia-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298365\" data-ts=\"1506685696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWPH\" target=\"_blank\">GWPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298365-gw-pharma-slips-15-premarket-on-zogenixs-successful-late-stage-study-of-zx008-in-dravet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GW Pharma slips 15% premarket on Zogenix&#39;s successful late-stage study of ZX008 in Dravet</a></h4><ul><li>GW Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a>) is down&nbsp;<font color='red'>15%&nbsp;</font>premarket, albeit on only 779 shares, in apparent response to Zogenix's announcement of positive Phase 3 results for Dravet syndrome candidate ZX008.</li><li>GW's late-stage candidate for Dravet is Epidiolex (cannabidiol).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298357-zogenixs-lead-candidate-zx008-successful-late-stage-dravet-study\" target=\"_blank\">Zogenix's lead candidate ZX008 successful in late-stage Dravet study</a> (Sept. 29)</li><li>Previously: <a href=\"https://seekingalpha.com/news/2439356-gw-pharma-initiates-second-phase-3-study-of-epidiolex-in-dravet-syndrome\" target=\"_blank\">GW Pharma initiates second Phase 3 study of Epidiolex in Dravet syndrome</a> (April 21, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298365\" data-linked=\"GW Pharma slips 15% premarket on Zogenix&#39;s successful late-stage study of ZX008 in Dravet\" data-tweet=\"$GWPH - GW Pharma slips 15% premarket on Zogenix&#39;s successful late-stage study of ZX008 in Dravet https://seekingalpha.com/news/3298365-gw-pharma-slips-15-premarket-on-zogenixs-successful-late-stage-study-of-zx008-in-dravet?source=tweet\" data-url=\"https://seekingalpha.com/news/3298365-gw-pharma-slips-15-premarket-on-zogenixs-successful-late-stage-study-of-zx008-in-dravet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298357\" data-ts=\"1506684657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZGNX\" target=\"_blank\">ZGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298357-zogenixs-lead-candidate-zx008-successful-in-late-stage-dravet-study-shares-up-212-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zogenix&#39;s lead candidate ZX008 successful in late-stage Dravet study; shares up 212% premarket</a></h4><ul><li>Zogenix (NASDAQ:<a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a>) is set for a big move today after <a href=\"https://seekingalpha.com/pr/16954943-zogenix-announces-positive-top-line-results-pivotal-phase-3-clinical-trial-zx008-dravet\" target=\"_blank\">announcing </a>positive results from a Phase 3 clinical trial assessing lead candidate ZX008 (low-dose fenfluramine hydrochloride) in patients with a rare and severe form of epilepsy called Dravet syndrome, a Fast Track-designated indication.</li><li>The 119-subject study met its primary endpoint of demonstrating superiority to placebo as measured by the change in the frequency of convulsive seizures from baseline (p&lt;0.001). All key secondary endpoints were also met.</li><li>ZX008 was generally well-tolerated with the occurrence of adverse events consistent with the known safety profile of fenfluramine. The incidence of treatment-emergent adverse events in the ZX008 cohort was 95.0% in the high dose (0.8 mg/kg/day) group and 94.9% in the low (0.2 mg/kg/day) dose group compared to 65.0% for placebo. The rates of serious adverse events in the three groups were 12.5%, 10.3% and 10.0%, respectively. Five participants discontinued treatment.</li><li>A second Phase 3, Study 1504, is underway.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>212%</font>&nbsp;premarket on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298357\" data-linked=\"Zogenix&#39;s lead candidate ZX008 successful in late-stage Dravet study; shares up 212% premarket\" data-tweet=\"$ZGNX - Zogenix&#39;s lead candidate ZX008 successful in late-stage Dravet study; shares up 212% premarket https://seekingalpha.com/news/3298357-zogenixs-lead-candidate-zx008-successful-in-late-stage-dravet-study-shares-up-212-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298357-zogenixs-lead-candidate-zx008-successful-in-late-stage-dravet-study-shares-up-212-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298353\" data-ts=\"1506683233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/V\" target=\"_blank\">V</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298353-cantor-fitzgerald-positive-on-visa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cantor Fitzgerald positive on Visa</a></h4><ul>     <li>Cantor Fitzgerald assumes coverage on Visa (NYSE:<a href='https://seekingalpha.com/symbol/V' title='Visa Inc.'>V</a>) with an Overweight rating.</li>     <li>\"Visa's competitive advantages include a dominant position in digital and strong strategic partnerships. For every dollar spent digitally, 43% is charged on a Visa card, nearly triple the 15% for every dollar spent at PoS (Point-of-Sale) locations,\" observes analyst Joseph Foresi.</li>     <li>The investment form assigns a price target of $120 to the payments stock to rep 15% upside potential.</li>     <li>Shares of VIsa are <font color='green'>up 0.96%</font> premarket to $105.58 vs. a 52-week trading range of $75.17 to $106.83.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298353\" data-linked=\"Cantor Fitzgerald positive on Visa\" data-tweet=\"$V - Cantor Fitzgerald positive on Visa https://seekingalpha.com/news/3298353-cantor-fitzgerald-positive-on-visa?source=tweet\" data-url=\"https://seekingalpha.com/news/3298353-cantor-fitzgerald-positive-on-visa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298348\" data-ts=\"1506682704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZGNX\" target=\"_blank\">ZGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298348-zogenix-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zogenix trading halted pending news</a></h4><ul><li>Nasdaq has <a href=\"http://www.nasdaqtrader.com/trader.aspx?id=tradehalts\" target=\"_blank\">suspended trading</a> in Zogenix (NASDAQ:<a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a>) pending the release of news.</li><li>A key looming event is the release of top-line data from a Phase 3 clinical trial,&nbsp;<a href=\"https://clinicaltrials.gov/ct2/show/NCT02682927?cond=Dravet+Syndrome&amp;intr=zx008&amp;spons=zogenix&amp;phase=2&amp;rank=3\" target=\"_blank\">Study 1</a>, assessing lead candidate ZX008 (low-dose fenfluramine) in young adults with a rare and severe form of epilepsy called Dravet syndrome. According to ClinicalTrials.gov, the estimated study completion date was September 1.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298348\" data-linked=\"Zogenix trading halted pending news\" data-tweet=\"$ZGNX - Zogenix trading halted pending news https://seekingalpha.com/news/3298348-zogenix-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3298348-zogenix-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":45,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}